Physician profile
Morris Kinast
NPI 1922045814
$2,457.01
in general payments reported to CMS, 2019-2025
29 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,835 · 2020: $280 · 2021: $342.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $668.41 | 2019-2020 | |
| Emd Serono, INC. | $333.31 | 2019 | |
| Ironshore Pharmaceuticals INC. | $221.09 | 2019 | |
| Corium, LLC | $120.27 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $119.29 | 2021 | |
| Eisai INC. | $116.16 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $114.66 | 2019 | |
| Novartis Pharmaceuticals Corporation | $107.27 | 2019 | |
| Sunovion Pharmaceuticals INC. | $100.99 | 2019-2020 | |
| Alexion Pharmaceuticals, INC. | $65.56 | 2019-2021 | |
| Sk Life Science, INC. | $53.26 | 2020-2021 | |
| Aquestive Therapeutics, INC. | $47.63 | 2019 | |
| Amgen INC. | $42.78 | 2019 | |
| Neos Therapeutics, LP | $38.19 | 2019 | |
| Lundbeck LLC | $37.98 | 2019 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $27.95 | 2020 | |
| Kyowa Kirin, INC. | $27.23 | 2019 | |
| Neurocrine Biosciences, INC. | $26.49 | 2019 | |
| Ge Healthcare | $24.84 | 2019 | |
| Allergan, INC. | $24.05 | 2021 | |
| Upsher-Smith Laboratories LLC | $22.96 | 2021 | |
| Acadia Pharmaceuticals INC | $18.56 | 2020 | |
| Scilex Pharmaceuticals INC. | $17.10 | 2019 | |
| Tanabe Pharma America, INC. | $16.59 | 2019 | |
| Jazz Pharmaceuticals INC. | $14.83 | 2021 | |
| Adlon Therapeutics L.P. | $13.14 | 2019 | |
| Avanir Pharmaceuticals, INC. | $12.89 | 2020 | |
| Amneal Pharmaceuticals LLC | $11.78 | 2019 | |
| Supernus Pharmaceuticals, INC. | $11.75 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Morris Kinast listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.